• Aptamer-based COVID-19 diagnostics

Aptamer Group advances COVID-19 testing capabilities with Integumen

Aptamer Group Ltd, the developer of diagnostic and therapeutic aptamer reagents, is pleased to announce further progress in their collaboration with Integumen plc (AIM: SKIN) to develop Microtox PD, a wastewater detection system for COVID-19. Aptamer Group is also collaborating with Integumen on the development of a new personalised rapid COVID-19 breath test, Microtx BT, […]

Aptamer Group and Cytiva form new collaboration for the development of COVID-19 Rapid Test

Collaboration to produce a rapid test for the COVID-19 coronavirus infection
Aptamer Group, is pleased to announce that it has entered into a collaboration with Cytiva, formerly known as GE Healthcare Life Sciences. The company will use its recently developed aptamer reagent combined with Cytiva’s lateral flow technology to produce a Lateral Flow Device (LFD)*. Aptamer […]

Aptamer Group making headlines on their Point of Care COVID19 reagent developments

 
Arron Tolley, CEO of Aptamer Group discusses the teams progress on COVID19 tests:
 

https://www.linkedin.com/feed/update/urn:li:activity:6678971478534324225

 

Aptamer based biosensors for rapid and sensitive detection of toxins

#aptamers #biosensors #toxins #aptasensors #sensitivedetection #rapiddetection #antibodyalternative #highselectivity #microbialdetection #foodsafety #smallmolecules #aptamergroup #COVID19research #aptamerscience
  • Aptamer-based COVID-19 diagnostics

Aptamers based ELISA for virus detection – A strong potential in combatting COVID-19 battle

27th April 2020
Currently, viral infection is a serious threat for human beings. The world is facing a global pandemic associated with the COVID-19 virus, for which virulence and infectious dose data are still emerging. With almost 3,025,732 confirmed cases of COVID-19 worldwide and 209,001 deaths as of 27th April 2020 as per WHO, accurate and […]